FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?

According to Zacks, Fortrea Holdings Inc. (FTRE) is currently a more attractive value investment than Illumina (ILMN). FTRE has a Zacks Rank of #2 (Buy) compared to ILMN's #3 (Hold), reflecting more impressive earnings estimate revisions. Key valuation metrics favor FTRE, including a lower forward P/E ratio (12.99 vs. 21.31), a lower PEG ratio (0.37 vs 1.77) and a lower P/B ratio (0.57 vs 6.03), leading to a Value grade of B for FTRE versus C for ILMN.

Analysis

Fortrea Holdings Inc. (FTRE) is presented as a more compelling value investment opportunity compared to Illumina (ILMN) within the Medical - Biomedical and Genetics sector, according to the provided Zacks analysis. FTRE currently holds a Zacks Rank of #2 (Buy), attributed to more impressive earnings estimate revision activity and an improving analyst outlook, which contrasts with ILMN's #3 (Hold) rank. Key valuation metrics underscore FTRE's relative attractiveness: its forward P/E ratio stands at 12.99, considerably lower than ILMN's 21.31. Furthermore, FTRE's PEG ratio of 0.37, which factors in expected EPS growth, is significantly more favorable than ILMN's 1.77. The price-to-book (P/B) ratio also highlights FTRE's value proposition at 0.57, starkly contrasting with ILMN's 6.03. These quantitative factors contribute to FTRE earning a Value grade of B, whereas ILMN receives a C. The per-ticker sentiment scores further reinforce this assessment, with FTRE at a strongly positive 0.8 and ILMN registering a negative -0.3, indicating a more positive market perception of FTRE's value characteristics.

Key Decisions for Investors

• Investors seeking value opportunities in the Medical - Biomedical and Genetics sector should consider Fortrea Holdings Inc. (FTRE) due to its superior Zacks Rank, positive earnings estimate revisions, and more attractive valuation multiples (P/E, PEG, P/B) relative to Illumina.
• Holders of Illumina (ILMN) or those considering it from a value perspective should note its less favorable valuation metrics, neutral Zacks Rank, and lower Value grade of C, suggesting a potentially less compelling value case at present.
• Closely monitor future earnings estimate revisions for both FTRE and ILMN, as these are significant drivers of their Zacks Ranks and can provide early indications of changes in their respective investment outlooks and value propositions.